Autologous chondrocyte implantation - Histogenics

Drug Profile

Autologous chondrocyte implantation - Histogenics

Alternative Names: NeoCart

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Histogenics Corporation
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cartilage disorders

Most Recent Events

  • 11 Jan 2017 Efficacy data from a pooled analysis of a phase I and phase II trial in Cartilage disorders released by Histogenics
  • 10 Nov 2016 Histogenics announces intention to submit BLA in 2018
  • 13 Nov 2015 Autologous chondrocyte implantation - Histogenics is available for licensing in (excluding USA) as of 13 Nov 2015. http://www.histogenics.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top